103 related articles for article (PubMed ID: 8085238)
1. A possible role for extracellular bicarbonate in U-46619-induced rat platelet aggregation.
Yokoyama K; Kudo I; Nakamura H; Inoue K
Thromb Res; 1994 May; 74(4):369-76. PubMed ID: 8085238
[TBL] [Abstract][Full Text] [Related]
2. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
4. Aggregation of human and canine platelets: modulation by purine nucleotides.
Soslau G; Arabe L; Parker J; Pelleg A
Thromb Res; 1993 Oct; 72(2):127-37. PubMed ID: 8303650
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
6. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
8. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.
Krauss AH; Woodward DF; Gibson LL; Protzman CE; Williams LS; Burk RM; Gac TS; Roof MB; Abbas F; Marshall K; Senior J
Br J Pharmacol; 1996 Mar; 117(6):1171-80. PubMed ID: 8882612
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
[TBL] [Abstract][Full Text] [Related]
10. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
11. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
12. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue.
Saklatvala J; Rawlinson L; Waller RJ; Sarsfield S; Lee JC; Morton LF; Barnes MJ; Farndale RW
J Biol Chem; 1996 Mar; 271(12):6586-9. PubMed ID: 8636072
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets.
Yin K; Lai PS; Rodriguez A; Spur BW; Wong PY
Prostaglandins; 1995 Sep; 50(3):169-78. PubMed ID: 8750213
[TBL] [Abstract][Full Text] [Related]
14. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
15. A possible dual physiological role of extracellular ATP in the modulation of platelet aggregation.
Soslau G; Youngprapakorn D
Biochim Biophys Acta; 1997 Feb; 1355(2):131-40. PubMed ID: 9042333
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye.
Krauss AH; Woodward DF; Burk RM; Gac TS; Gibson LL; Protzman CE; Abbass F; Marshall K; Senior J
J Ocul Pharmacol Ther; 1997 Aug; 13(4):303-12. PubMed ID: 9261766
[TBL] [Abstract][Full Text] [Related]
18. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
Sanderson HM; Heptinstall S; Vickers J; Lösche W
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):245-8. PubMed ID: 8735830
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
20. DIDS-sensitive pHi regulation in single rat cardiac myocytes in nominally HCO3-free conditions.
Wu ML; Tsai ML; Tseng YZ
Circ Res; 1994 Jul; 75(1):123-32. PubMed ID: 8013070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
